Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Leon Cooperman Likes These Healthcare and Tech Stocks

Page 1 of 2

Billionaire Leon Cooperman is one of the best value investors on the Street who scored high returns by betting on undervalued companies. Since 1991, when Cooperman founded Omega Advisors, the fund has returned a cumulative 1,536.2%, according to a recent investor conference call. In the third quarter, amid a broader market sell-off, Omega’s holdings lost around 15%, but the investor remained bullish on most of his positions. In previous articles we have discussed Cooperman’s top picks as of October 16, as well as his cheapest stocks in terms of forward P/E. In this article, we are going to take a look at two healthcare stocks and three tech stocks that Omega had among its top 25 holdings as of October 16.


Omega Advisors is one of some 730 hedge funds that we follow under our small-cap strategy. Through extensive research, we determined that the best way to imitate the hedge funds’ activity is to follow their 15 most popular small-cap stock picks. In backtests, this approach showed monthly returns nearly 1.0 percentage points above the market (read about our backtests). Our strategy has returned 102% since August 2012, and has outperformed the S&P 500 ETF (SPY) by some 53 percentage points.

Leon Cooperman
Leon Cooperman
Omega Advisors

Allergan PLC (NYSE:AGN) represents Omega’s largest healthcare holding as of October 16, amassing 3% of its assets. The fund reported ownership of 922,375 shares in its last 13F filing, the position being the largest in terms of value at the end of June. Allergan PLC (NYSE:AGN) ranked as the most popular pick among the funds from our database, being included in the equity portfolios of 151 funds, which held in aggregate over 17% of the company’s stock at the end of June. Allergan’s shares lost around 10% during the third quarter and are trading cheap at 11.3 times 2016 earnings, according to Omega. Another investor bullish on Allergan PLC (NYSE:AGN) is Larry Robbins of Glenview Capital (see his take on the company). Glenview held 1.98 million shares of Allergan at the end of June.

Follow Allergan Plc (NYSE:AGN)
Trade (NYSE:AGN) Now!

Just yesterday, it was confirmed that Allergan might be acquired by Pfizer Inc. (NYSE:PFE), which represents Cooperman’s second healthcare pick. Omega did not report holding shares of Pfizer in its latest 13F, but during the conference call, it revealed that the stake amassed 2.1% of its assets. Pfizer Inc. (NYSE:PFE)’s stock did not react much on the back of acquisition talks announcement, while Allergan’s shares closed 6% higher. The terms of the deal are unknown yet, but there is a high chance that it will include an inversion, with Pfizer moving its headquarters to Ireland in order to pay lower taxes. As a reaction, billionaire activist Carl Icahn said via Twitter: “The situation is much more dangerous than most people believe,” as he is trying to pursue the Congress to initiate an international tax reform. Meanwhile, billionaire Ken Fisher’s Fisher Asset Management disclosed ownership of 31.93 million shares of Pfizer Inc. (NYSE:PFE) in its 13F filing for the third quarter

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

Let’s move on to Omega’s top tech picks held as of October 16, Alphabet Inc (NASDAQ:GOOGL), Motorola Solutions Inc (NYSE:MSI), and Facebook Inc (NASDAQ:FB), which we will discuss on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!